TL;DR:
- Henlius USA and OncoHost join forces to employ machine learning and biomarker analysis in predicting Phase III clinical trial outcomes for serplulimab.
- AI and machine learning are revolutionizing clinical trial assessment, as demonstrated by MIT and Dassault’s recent advancements.
- OncoHost’s PROphet platform combines aptamer-based assays and machine learning for patient selection, survival prediction, mechanism discovery, adverse event anticipation, and response forecasting.
- The platform will analyze serplulimab Phase III trial biomarkers to identify resistance patterns.
- The Phase III trial evaluates serplulimab’s efficacy and safety versus chemotherapy plus atezolizumab in previously untreated ES-SCLC patients.
- AI and machine learning have been used for patient recruitment and outcome prediction, with the metaverse’s value predicted to reach $627 billion by 2030.
- Henlius offers an impressive portfolio of immuno-oncology drugs, including serplulimab and Hanlikang.
Main AI News:
In a bold move towards harnessing the power of cutting-edge technology, Hengenix Biotech (Henlius USA) has joined forces with OncoHost, a frontrunner in the field of predictive analytics. Their partnership aims to revolutionize the landscape of clinical trials by leveraging the potential of machine learning and biomarker analysis to foresee the outcomes of the Phase III clinical trial for serplulimab.
The infusion of artificial intelligence (AI) and machine learning into the realm of drug and device development has gained momentum in recent years. Notably, in 2019, the Massachusetts Institute of Technology pioneered the use of AI techniques to evaluate the prospects of clinical trials, heralding a new era of data-driven decision-making. Last month, Dassault introduced ‘Emma,’ a digital twin designed to simulate and evaluate medical devices, further enhancing patient engagement with clinical trials.
At the heart of this collaboration lies OncoHost’s groundbreaking PROphet platform, a cutting-edge system that meticulously analyzes blood samples using aptamer-based assays. The platform’s pièce de résistance is its ability to deploy sophisticated machine learning models, which serve a multitude of functions, including patient selection, prognosis prediction (encompassing overall survival and progression-free survival), mechanism of action discovery, adverse event anticipation, and response forecasting.
Specifically, the PROphet platform will embark on a comprehensive analysis of the biomarkers within the serplulimab Phase III trial (NCT05468489) cohort. Its mission is to unveil the intricate patterns of resistance prevalent among the recruited patient population.
The Phase III trial, conducted with an open-label approach, endeavors to juxtapose the efficacy and safety profiles of serplulimab with chemotherapy (carboplatin-etoposide), combined with the prevailing standard of care, atezolizumab plus chemotherapy. This trial marks a critical milestone in advancing treatment options for patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC) who were previously untreated in the United States.
The integration of AI in healthcare has witnessed prior applications, including the analysis of patient medical records for trial recruitment and the utilization of machine learning models to scrutinize pathology samples, ultimately predicting outcomes in terms of overall survival and progression-free survival. According to forecasts by GlobalData, the metaverse, bolstered by AI and machine learning technology, is projected to reach a staggering worth of $627 billion by the year 2030.
It’s worth noting that GlobalData, the visionary parent company of Clinical Trials Arena, is keeping a close watch on these developments.
Intriguingly, Henlius’ expansive product portfolio boasts a collection of immuno-oncology drugs, all of which have received regulatory approval in China. Notable among them is Hansizhuang (serplulimab), a pioneering anti-PD-1 monoclonal antibody, along with Hanlikang, a rituximab biosimilar that promises to further diversify and enhance the treatment options available to patients.
Conclusion:
The partnership between Henlius and OncoHost represents a significant advancement in the use of AI and biomarker analysis to forecast clinical trial outcomes. This strategic collaboration underscores the industry’s commitment to innovation and precision medicine, potentially reshaping the healthcare landscape and offering hope to patients seeking effective treatments. The integration of AI in healthcare is poised to play a pivotal role in shaping the future of the pharmaceutical market, with substantial growth and transformation expected in the coming years.
